United States Patent 6,670,351 (Oxandrolone)
What is the invention and what do the claims cover?
US Drug Patent 6,670,351 claims a method of treating HIV-associated myopathy and muscle wasting in an AIDS patient using oxandrolone.
Independent claim
- Claim 1: A method for ameliorating HIV-associated myopathy and muscle wasting in an AIDS patient comprising administering a therapeutically effective amount of oxandrolone.
Core claim structure
Across the dependent claims, the patent narrows along four axes:
- Dose range (daily total)
- Route of administration (oral plus multiple non-oral routes)
- Dosage form (tablet for oral embodiments)
- Dosing schedule/duration (time period and unit-dose frequency)
How broad is the claim scope on dose, route, duration, and regimen?
Below is the claim-by-claim “scope map” based strictly on the claim text you provided.
1) Daily dose scope
- Claim 2: daily dosage 2.5 to 30 mg
- Claim 3: daily dosage 2.5 to 20 mg
- Claim 4: daily dosage about 20 mg (within Claim 3 range)
- Claim 5: daily dosage about 15 mg (within Claim 3 range)
Practical implication: The patent covers a relatively wide “therapeutic effective amount” space, with explicit daily targets anchored at 2.5-30 mg and further refined to 2.5-20 mg, plus specific exemplars 20 mg and 15 mg.
2) Route of administration scope
The claims include multiple administration modalities:
- Oral: Claims 6, 8, 10, 12, 14
- Oral dosage form: tablet under the oral branches (Claims 7, 9, 11, 13, 15)
- Percutaneous: Claim 22
- Intravenous: Claim 23
- Intramuscular: Claim 24
- Sublingual: Claim 25
- Transdermal: Claim 26
Practical implication: Even though HIV muscle-wasting treatment in the market has historically emphasized oral anabolic steroids, this patent claims broad administration paths, reducing design-around leverage based on route.
3) Treatment duration scope
- Claim 16: daily administration for about 2 weeks to about 6 months
- Parallel route-specific duration claims:
- Claims 17, 18, 19, 20, 21 for the corresponding oral/tablet embodiments (through Claim 14’s chain)
Practical implication: The method is anchored to a discrete treatment window rather than open-ended chronic use.
4) Unit-dose frequency scope
Two frequency regimes appear:
Regime A (3 times daily)
- Claims 27–31: unit dose about 2 to about 5 mg three times daily
(Claims 27–31 depend on Claim 1, 2, 3, 4, 5 respectively)
Regime B (3 or 4 times daily)
- Claims 32–36: unit dose about 1 to about 5 mg three or four times daily
(Claims 32–36 depend on Claim 1, 2, 3, 4, 5 respectively)
Practical implication: The claims cover both standard “TID” style regimens and more granular dosing frequency (3 or 4 daily), with unit doses spanning 1-5 mg.
Does the claim language limit the target population to “AIDS patient” specifically?
Yes. The method is framed as use in an AIDS patient with HIV-associated myopathy and muscle wasting. The scope depends on that patient characterization and the medical condition match:
- Target disease state in the claim: HIV-associated myopathy and muscle wasting
- Target status: AIDS patient
This matters for both enforcement and invalidity because it ties the claim to specific clinical endpoints and labeling-like therapeutic intent.
Patent Landscape Analysis
What is the competitive landscape likely to look like around oxandrolone for HIV muscle wasting?
From a claim-scope perspective, US 6,670,351 positions oxandrolone as a direct method-of-use patent for a specific HIV/AIDS muscle-wasting indication, using therapeutically effective dosing with explicit dose/frequency/route limitations.
What this means competitively
- Direct competitors: other therapies claiming to ameliorate HIV-associated myopathy/muscle wasting in AIDS patients, whether by:
- different anabolic steroids,
- non-steroidal agents,
- growth hormone/secretagogues,
- anti-cachexia agents,
- or combination regimens.
- Design-around paths are constrained by the breadth of administration routes claimed (oral plus non-oral), and by multiple explicit dose/frequency ranges.
What is most likely to be “adjacent”
- Method-of-use claims for muscle wasting/cachexia in HIV/AIDS using anabolic steroids or other agents.
- Formulation and dosing patents may be adjacent, but this patent’s core claim is a method tied to a specific drug (oxandrolone) and a specific clinical context.
Where is the enforcement “pinch point” for future entrants?
The pinch point is that infringement analysis for method claims generally turns on whether an accused regimen matches the claimed steps:
- Drug: oxandrolone
- Patient/indication: AIDS with HIV-associated myopathy and muscle wasting
- Administered method: therapeutically effective amount
- Claim 1 alone already covers “therapeutically effective amount.” Dependent claims add explicit boundaries, but claim 1 is the broad anchor.
Impact of dependent claims
Even if a product or clinical protocol falls outside the specific dose or regimen ranges in dependent claims, claim 1 can still capture it if the dosing qualifies as “therapeutically effective” for the claimed condition.
How should one read the dose ranges for freedom-to-operate planning?
US 6,670,351 supplies multiple “numerical hooks”:
- Daily dose ranges: 2.5-30 mg and 2.5-20 mg
- Fixed daily examples: 15 mg and 20 mg
- Frequency + unit dose: 1-5 mg at TID or QID, or 2-5 mg at TID
- Duration: 2 weeks to 6 months
From a risk-control standpoint, those numbers are exactly where clinicians, label design, and trial protocols can unintentionally line up with claimed embodiments.
How do route claims affect design-around strategies?
The patent includes:
- oral (tablet)
- percutaneous
- intravenous
- intramuscular
- sublingual
- transdermal
This undermines a common FTO move of changing route while keeping the same API and indication. Unless a competitor uses a materially different therapy or frames the clinical objective outside “HIV-associated myopathy and muscle wasting in an AIDS patient,” route alone likely does not avoid exposure.
Claim Strength and Vulnerability (Based on Text-Only Claim Content)
What makes this patent strong on paper?
- Specific drug + specific indication: oxandrolone + HIV-associated myopathy/muscle wasting in AIDS patients.
- Broad independent claim: Claim 1 uses “therapeutically effective amount,” which is not a rigid numerical limitation.
- Multiple dependent anchors: dose windows, specific daily doses, route, dosage form, unit dose frequency, and duration create multiple ways to map an accused regimen to the claims.
What features could drive challenge or limitation arguments?
This patent’s vulnerability often comes from interpretation rather than from the face of claim text:
- “AIDS patient” and “HIV-associated myopathy and muscle wasting” require a definable clinical condition, which can become a claim construction and proof issue.
- “Therapeutically effective amount” invites disputes about what dose is “effective” for the claimed use in the specific condition.
Those points do not negate the claim, but they define where factual and legal battles tend to concentrate.
Actionable Takeaways for R&D and Investment
Key Takeaways
- US 6,670,351 is a method-of-treatment patent: it claims oxandrolone administered to AIDS patients to ameliorate HIV-associated myopathy and muscle wasting.
- Claim 1 is the broadest enforcement anchor: it covers any therapeutically effective amount meeting the method purpose.
- Dependent claims add explicit numerical and operational constraints that can tightly match real-world and trial dosing:
- daily total: 2.5-30 mg and 2.5-20 mg, plus ~15 mg and ~20 mg
- duration: ~2 weeks to ~6 months
- unit doses: ~2-5 mg TID and ~1-5 mg TID or QID
- routes: oral (tablet) plus IV, IM, sublingual, transdermal, and percutaneous.
- The broad route coverage reduces the effectiveness of route-based design-around strategies if the regimen is otherwise the same.
FAQs
1) What does Claim 1 cover in plain terms?
A method where oxandrolone is administered in a therapeutically effective amount to an AIDS patient to ameliorate HIV-associated myopathy and muscle wasting.
2) What daily dose ranges are explicitly claimed?
Two explicit ranges: about 2.5 to about 30 mg/day (Claim 2) and about 2.5 to about 20 mg/day (Claim 3), plus specific daily amounts about 15 mg (Claim 5) and about 20 mg (Claim 4).
3) Does the patent require oral dosing?
No. It claims oral dosing (with tablets) and also includes non-oral embodiments (percutaneous, IV, IM, sublingual, transdermal).
4) What treatment duration is claimed?
Administration daily for about 2 weeks to about 6 months.
5) Is the frequency limited?
The patent includes unit-dose frequency embodiments: about 2-5 mg three times daily and about 1-5 mg three or four times daily.
References
[1] United States Patent 6,670,351. “Method for ameliorating HIV-associated myopathy and muscle wasting in an AIDS patient.” Claims 1-36 (as provided in user prompt).
